Vaccines
Philip Dormitzer explained that there are plenty of reasons to be excited about the prophylactic and therapeutic potential of mRNA.
This marks the second vaccine against the novel coronavirus developed by the India-based company and brings a significant milestone for intranasal formulations.
President Joe Biden took an aggressive step that mandates vaccination for 100 million Americans who are eligible for preventative medication.
A recently published study points to a previous SARS infection—plus vaccination—as the key to a robust immunity against SARS-CoV-2.
Norovirus vaccine is being developed at a rapid pace. HilleVax invests $135 million to rapidly progress the development. Here’s more about the vaccine.
Celsion announced results from its PLACCINE DNA vaccine platform that showed it produced antibodies and cytotoxic T-cell response specific to the spike antigen of SARS-CoV-2.
A study published in The Lancet Infectious Diseases found that the Pfizer-BioNTech, Oxford-AstraZeneca or Moderna vaccines resulted in a drop in “long-haul” COVID-19 by 50%.
New data is coming out every day about COVID-19 and the body’s response to vaccines. Here’s a look at some of the top stories.
Belgium researchers compared the Moderna and Pfizer-BioNTech COVID-19 vaccines and found that the Moderna jabs generated twice the antibodies than the Pfizer-BioNTech vaccine.
Marion Gruber, director of the agency’s Office of Vaccines Research & Review is leaving at the end of October. Phil Krause, OVRR’s deputy director, is exiting in November.
PRESS RELEASES